Redmile Group, LLC's Form 4 filing
Entrada Therapeutics, Inc. (TRDA) · filed Nov 4, 2021
- Accession no.
- 0001104659-21-134623
- Filed
- Nov 4, 2021, 9:00 PM ET
- Trade date
- Nov 2, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market purchases total $20.0M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Redmile Group, LLCCIK 0001425738 | 10% Owner |
| Green JeremyCIK 0001650527 | 10% Owner |
| Redmile Biopharma Investments III, L.P.CIK 0001838746 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 2, 2021 | Common Stock | CConversionAcquired | +954,420 | –F1 | – | 954,420 | Indirect | |
| Nov 2, 2021 | Common Stock | PPurchaseAcquired | +1,000,000 | $20.00 | +$20,000,000 | 1,954,420 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 2, 2021 | Common Stock | CConversionDisposed | −954,420 | $0.00 | $0 | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The Series B convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering for no consideration. The Series B convertible preferred stock had no expiration date.
Referenced by the price of 1 transaction in Table I.